Cabazitaxel

Active substance
Cabazitaxel
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
Generic
Main indication
Prostate cancer
Extended indication
Cabazitaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

1. Product

Current proprietary name
Jevtana (Sanofi-Aventis)
Proprietary name
Cabazitaxel Accord
Manufacturer
Accord Healthcare
Mechanism of action
Cytostatic

2. Registration

Registration route
Centralised (EMA)
Submission date
June 2019
Expected Registration
June 2020
Registration phase
Positive CHMP opinion
Additional comments
SPC Jevtana verloopt op 21-03-2026. Positieve CHMP-opinie in april 2020.

3. Therapeutic value

Therapeutic value
Potential equal value
Duration of treatment
Not found

4. Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

5. Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

6. Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.